IM
IMRN.US Immuron Ltd ADR
- Market cap
- USD 7.06M
- P/E
- -
- P/B
- 0.94x
- ROE
- -34.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IMRN.US undervalued?
Graham numberThe Graham number of Immuron Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immuron Ltd ADR fundamental analysis
No fundamental analysis for Immuron Ltd ADR yet.
Immuron Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as …
Full company profileImmuron Ltd ADR financial statements
Immuron Ltd ADR annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.40M | 1.84M | 2.39M | 2.52M | 146K | 765K | 1.80M | 4.90M | 7.29M | 7.55M |
| Gross Profit | 922K | 1.26M | 1.71M | 1.83M | -665K | 524K | 1.74M | 3.34M | 4.77M | 4.87M |
| Operating Income | -8.39M | -2.99M | -4.66M | -2.92M | -8.38M | -2.87M | -3.57M | -5.80M | -5.34M | -4.63M |
| EBITDA | -8.39M | -3.24M | -4.70M | -2.87M | -7.92M | -3.09M | -3.36M | -5.17M | -5.31M | -4.63M |
| Net Income | -6.80M | -3.01M | -4.66M | -2.90M | -8.38M | -2.85M | -3.79M | -6.94M | -5.22M | -3.75M |
| EPS | -2.57 | -0.90 | -1.29 | -0.66 | -1.52 | -0.50 | -0.66 | -1.22 | -0.90 | -0.50 |
| Balance Sheet | ||||||||||
| Total Assets | 8.29M | 9.24M | 8.56M | 6.20M | 27.1M | 24.9M | 22.0M | 15.5M | 10.1M | 13.0M |
| Total Liabilities | 1.71M | 803K | 1.21M | 558K | 1.16M | 1.68M | 2.37M | 2.84M | 2.06M | 1.99M |
| Shareholders' Equity | 6.57M | 8.44M | 7.35M | 5.64M | 25.9M | 23.2M | 19.6M | 12.7M | 8.03M | 11.0M |
| Cash & Short-term Investments | 3.99M | 4.73M | 5.12M | 3.25M | 25.0M | 22.1M | 19.0M | 11.7M | 5.87M | 9.02M |
| Total Debt | 366K | 0.00 | 0.00 | 61.1K | 20.5K | 210K | 189K | 173K | 117K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -7.03M | -3.50M | -1.29M | -3.16M | -3.05M | -3.13M | -2.49M | -5.88M | -6.14M | -3.00M |
| Capital Expenditure | 5.70K | 6.59K | 1.47K | 864.00 | 4.94K | 10.0K | 7.74K | 195.00 | 2.00 | 4.65K |
| Free Cash Flow | -7.04M | -3.51M | -1.29M | -3.17M | -3.05M | -3.14M | -2.50M | -5.88M | -6.14M | -3.00M |
| Ratios | ||||||||||
| ROE | -103.5% | -35.7% | -63.3% | -51.5% | -32.4% | -12.3% | -19.3% | -54.6% | -64.9% | -34.1% |
| ROA | -82.1% | -32.6% | -54.4% | -46.8% | -31.0% | -11.5% | -17.2% | -44.6% | -51.7% | -28.9% |
| Net Profit Margin | -487.3% | -163.4% | -195.0% | -115.3% | -5,751.6% | -373.0% | -209.8% | -141.5% | -71.6% | -49.8% |
| Debt to Equity | 0.06x | 0.00x | 0.00x | 0.01x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immuron Ltd ADR dividends
Immuron Ltd ADR has not paid dividends in the last 10 fiscal years.
Who owns Immuron Ltd ADR
- Insiders 0.28%
- Institutions 2.02%
- Public & others 97.70%
- Shares outstanding 8.07M
- Free float 6.87M
Top institutions holding IMRN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 43.1K | 0.53% | +212.40% | Jun 2026 |
| HRT FINANCIAL LLC | 20.6K | 0.26% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 5.20K | 0.06% | +13.04% | Jun 2026 |
| Rhumbline Advisers | 3.84K | 0.05% | -47.94% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 1.70K | 0.02% | -94.44% | Jun 2026 |
| UBS Group AG | 363.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Immuron Ltd ADR company profile
- Company name
- Immuron Ltd ADR
- Ticker
- IMRN.US
- Exchange
- USA Stocks
- Listed since
- Jun 9, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- June
- Address
- 62 Lygon Street, Carlton, VIC, Australia, 3053
- Phone
- 61 3 8892 4854
- Website
- immuron.com.au
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Immuron Ltd ADR management
6- Mr. Steven George Lydeamore CPA, M.B.A.Chief Executive Officer · born 1968
- Dr. Jerry Kanellos Ph.D.Chief Scientific Officer · born 1961
- Mr. Flavio PalumboChief Commercial Officer · born 1974
- Mr. Aaron LauritaChief Financial Officer
- Mr. David LyonHead of Marketing
- Ms. Olga SmejkalovaCompany Secretary